Table of Contents

company-logo

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy; and FTX-6058, an investigational oral fetal hemoglobin inducer for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has research and discovery collaboration agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and has a strategic collaboration and license agreement with MyoKardia, Inc. to discover, develop, and commercialize novel targeted therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Fulcrum Therapeutics Dividend Announcement

• Fulcrum Therapeutics does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on Fulcrum Therapeutics dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

Fulcrum Therapeutics Dividend History

Fulcrum Therapeutics Dividend Yield

Fulcrum Therapeutics current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Fulcrum Therapeutics stock? Use our calculator to estimate your expected dividend yield:

Fulcrum Therapeutics Financial Ratios

P/E ratio-13.97
PEG ratio-0.14
P/B ratio0.97
ROE-7.31%
Payout ratio0.00%
Current ratio18.44
Quick ratio18.44
Cash Ratio5.01

Fulcrum Therapeutics Dividend FAQ

Does Fulcrum Therapeutics stock pay dividends?
Fulcrum Therapeutics does not currently pay dividends to its shareholders.
Has Fulcrum Therapeutics ever paid a dividend?
No, Fulcrum Therapeutics has no a history of paying dividends to its shareholders. Fulcrum Therapeutics is not known for its dividend payments.
Why doesn't Fulcrum Therapeutics pay dividends?
There are several potential reasons why Fulcrum Therapeutics would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will Fulcrum Therapeutics ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While Fulcrum Therapeutics has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is Fulcrum Therapeutics a dividend aristocrat?
Fulcrum Therapeutics is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is Fulcrum Therapeutics a dividend king?
Fulcrum Therapeutics is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is Fulcrum Therapeutics a dividend stock?
No, Fulcrum Therapeutics is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy Fulcrum Therapeutics stocks?
To buy Fulcrum Therapeutics you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy Fulcrum Therapeutics stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.